 |
49 Diseases |  |
64 Trials |
|
64 Trials |  |
670 News |  |
| «1234567891011» |
- | prednisone delayed-release tablet / Generic mfg.
Journal, Oncolytic virus: Contour Connections: Early Interest in a Program to Connect International Radiation Oncologists for Virtual Cloud-Based Contouring and Treatment Plan Evaluation. (Pubmed Central) - Oct 29, 2021
Contour Connections seeks to address this demand by actively recruiting individuals to utilize a virtual cloud-based platform to review contours and treatment plans with each other. This study demonstrates that recruitment is readily feasible within the global radiation oncology community, with early results showing a favorable participant experience.
- || prednisone delayed-release tablet / Generic mfg.
Clinical, Journal: Impact of the Novel Contrast Agent Gadopiclenol on Decision Making in Patients With Brain Metastases. (Pubmed Central) - Oct 29, 2021
Gadopiclenol improved BM detection and characterization with impact on RT treatment decisions. Further trials are warranted to determine the impact of this novel MRI contrast agent on a clinical setting.
- || prednisone delayed-release tablet / Generic mfg.
@DrTedros deja los rayos de sol (Twitter) - Oct 26, 2021
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 22, 2021
P2, N=58, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Further trials are warranted to determine the impact of this novel MRI contrast agent on a clinical setting. Suspended --> Active, not recruiting
- | Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Trial initiation date, Trial suspension, Combination therapy: Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 12, 2021
P1, N=24, Suspended, Sponsor: Yazeed Sawalha
Suspended --> Active, not recruiting Initiation date: May 2021 --> Dec 2021 | Not yet recruiting --> Suspended
- | Journal: Ozanimod (Zeposia) for ulcerative colitis. (Pubmed Central) - Oct 7, 2021
Initiation date: May 2021 --> Dec 2021 | Not yet recruiting --> Suspended No abstract available
- | prednisone delayed-release tablet / Generic mfg.
JAJAJAJAJAJAJAJAJA RAYOS. (Twitter) - Sep 24, 2021
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 5, 2021
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
No abstract available Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Jun 2027 --> Dec 2027
- | Elzonris (tagraxofusp) / Menarini, Nippon Shinyaku
New P1/2 trial: Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Sep 1, 2021
P1/2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | abiraterone acetate / Generic mfg.
Biomarker, Trial completion date, Trial primary completion date: Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms (clinicaltrials.gov) - Sep 1, 2021
P1, N=20, Active, not recruiting, Sponsor: Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair
Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Jun 2027 --> Dec 2027 Trial completion date: Jun 2021 --> Jul 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- | Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment open, Combination therapy: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Sep 1, 2021
P3, N=192, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2021 --> Jul 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Suspended --> Recruiting
- || prednisone delayed-release tablet / Generic mfg.
¡Rayos! Y esas son las medidas del presi. Por eso estamos como estamos, no hay medidas que se cumplan y debemos salir a trabajar. (Twitter) - Aug 24, 2021
- | Venclexta (venetoclax) / Roche, AbbVie
Trial suspension: A051701: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (clinicaltrials.gov) - Aug 18, 2021
P2/3, N=374, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date, Metastases: CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) - Aug 18, 2021
P1, N=12, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Suspended Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - Aug 12, 2021
P2, N=48, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022 Recruiting --> Active, not recruiting | Trial completion date: Jan 2022 --> May 2022 | Trial primary completion date: Jan 2022 --> May 2022
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Talzenna (talazoparib) / Pfizer
Enrollment open, Trial completion date, Trial primary completion date: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov) - Aug 12, 2021
P2, N=70, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | Trial completion date: Jan 2022 --> May 2022 | Trial primary completion date: Jan 2022 --> May 2022 Not yet recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- | Zejula (niraparib) / GSK, J&J
Enrollment open, Metastases: Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer (clinicaltrials.gov) - Aug 8, 2021
P2, N=200, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Not yet recruiting --> Recruiting
- | prednisone delayed-release tablet / Generic mfg.
Journal: Mónico Sánchez Moreno: a pioneer in radiologic technology. (Pubmed Central) - Aug 3, 2021
Her efforts made it possible to have an affordable device made in Spain that would allow radiological examinations to be done in places where it would have been otherwise unthinkable. In conclusion, Mónico Sánchez Moreno was a self-made woman who deserves to be remembered for her pioneering role in portable radiology.
- | prednisone delayed-release tablet / Generic mfg.
Journal: Vitamin D for daily practice (Pubmed Central) - Aug 1, 2021
Measurement in the body is performed by determining 25-hydroxycholecalciferol with values below 20ng/ml being considered insufficient. Universal screening of vitamin D is not currently recommended, only in situations where a deficiency is suspected.
- | Monjuvi (tafasitamab-cxix) / MorphoSys, Xencor, Incyte, Specialised Therap, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Calquence (acalabrutinib) / AstraZeneca
New P2 trial: Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study (clinicaltrials.gov) - Jul 27, 2021
P2, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | prednisone delayed-release tablet / Generic mfg.
no tía, pero rayos X sí (Twitter) - Jul 22, 2021
- || prednisone delayed-release tablet / Generic mfg.
Clinical, Journal: Extrathoracic manifestations of COVID-19 in adults and presentation of the disease in children. (Pubmed Central) - Jul 21, 2021
This paper aims to provide answers to these questions. To this end, we describe and illustrate the extrathoracic imaging manifestations of COVID-19 in adults as well as the entire spectrum of imaging findings in children.
- ||| prednisone delayed-release tablet / Generic mfg.
Sí pues.... con esas restricciones, habría despidos masivos y si nos quedamos sin Trabajo ¿Nos va a mantener de su bolsillo o qué rayos? Cuando usted estuvo su COPRECOVID solo fue un gasto y no sirvió de nada, como lo de los cacerolazos a las 08:00 p.m. nos costó esas ideas 10 M. (Twitter) - Jul 9, 2021
- || prednisone delayed-release tablet / Generic mfg.
Clinical, Journal: Extrathoracic manifestations of COVID-19 in adults and presentation of the disease in children. (Pubmed Central) - Jul 7, 2021
This paper aims to provide answers to these questions. To this end, we describe and illustrate the extrathoracic imaging manifestations of COVID-19 in adults as well as the entire spectrum of imaging findings in children.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 2, 2021
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
To this end, we describe and illustrate the extrathoracic imaging manifestations of COVID-19 in adults as well as the entire spectrum of imaging findings in children. Trial primary completion date: Jun 2021 --> Jun 2022
- | Zejula (niraparib) / GSK, J&J
New P2 trial, Metastases: Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer (clinicaltrials.gov) - Jun 30, 2021
P2, N=200, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial suspension, Combination therapy: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Jun 28, 2021
P3, N=192, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2021 --> Jun 2022 Recruiting --> Suspended
- || prednisone delayed-release tablet / Generic mfg.
Clinical, Journal: Minimal Erythema Dose: Correlation with Fitzpatrick Skin Type and Concordance Between Methods of Erythema Assessment in a Patient Sample in Colombia. (Pubmed Central) - Jun 26, 2021
Concordance correlation coefficients between the different methods of erythema assessment were very good. Correlations between MEDs and skin types were moderate to good.
- ||| itacitinib (INCB039110) / Incyte
Trial completion date: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Jun 23, 2021
P2/3, N=431, Recruiting, Sponsor: Incyte Corporation
Correlations between MEDs and skin types were moderate to good. Trial completion date: Feb 2025 --> Apr 2024
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open, Checkpoint inhibition, Checkpoint block, Metastases: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov) - Jun 23, 2021
P1, N=16, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Feb 2025 --> Apr 2024 Suspended --> Recruiting
- | Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment open, Combination therapy: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Jun 15, 2021
P3, N=192, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Not yet recruiting --> Recruiting
- || Darzalex (daratumumab) / J&J
Enrollment open: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma (clinicaltrials.gov) - Jun 11, 2021
P1, N=15, Recruiting, Sponsor: AIDS Malignancy Consortium
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial primary completion date: AHOD1331: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (clinicaltrials.gov) - Jun 7, 2021
P3, N=600, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Trial primary completion date: Jun 2021 --> Dec 2021
- | prednisone delayed-release tablet / Generic mfg.
Journal: Marie Curie: how to break the glass ceiling in science and in radiology. (Pubmed Central) - Jun 6, 2021
Being the first woman to break through so many barriers in a totally male-dominated science makes her an emblematic figure in the fight for equal opportunities and human rights. This article reviews her most important contributions to science in general and to diagnostic radiology in particular through her participation in the French military's radiological plan during the First World War.
- | Rituxan (rituximab) / Roche
Trial completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jun 3, 2021
P2, N=349, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
This article reviews her most important contributions to science in general and to diagnostic radiology in particular through her participation in the French military's radiological plan during the First World War. Trial completion date: Dec 2021 --> Jan 2027
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition, Checkpoint block, Metastases: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov) - May 26, 2021
P1, N=16, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2021 --> Jan 2027 Trial completion date: May 2021 --> May 2022 | Trial primary completion date: May 2021 --> May 2022
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Trial completion, Trial completion date, Trial primary completion date: NCI-2018-01064: Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer (clinicaltrials.gov) - May 18, 2021
P2, N=86, Completed, Sponsor: M.D. Anderson Cancer Center
Trial completion date: May 2021 --> May 2022 | Trial primary completion date: May 2021 --> May 2022 Active, not recruiting --> Completed | Trial completion date: Feb 2022 --> May 2021 | Trial primary completion date: Feb 2022 --> May 2021
- | prednisone delayed-release tablet / Generic mfg.
Clinical, Journal: Comparative thermal map of the foot between patients with and without diabetes through the use of infrared thermography. (Pubmed Central) - May 15, 2021
Active, not recruiting --> Completed | Trial completion date: Feb 2022 --> May 2021 | Trial primary completion date: Feb 2022 --> May 2021 The use of infrared thermography in the evaluation of the foot at risk could demonstrate the variability of temperature by study area, which could be useful in the area of healthcare for the diagnosis and prevention of injuries to compromised areas of the foot.
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Roche
Enrollment open, Checkpoint inhibition: PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (clinicaltrials.gov) - May 12, 2021
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
The use of infrared thermography in the evaluation of the foot at risk could demonstrate the variability of temperature by study area, which could be useful in the area of healthcare for the diagnosis and prevention of injuries to compromised areas of the foot. Not yet recruiting --> Recruiting
- || Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
Trial initiation date, Combination therapy: NCI-2021-01791: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - May 10, 2021
P1, N=20, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting Initiation date: May 2021 --> Aug 2021
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial suspension, Checkpoint inhibition, Checkpoint block, Metastases: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov) - May 6, 2021
P1, N=16, Suspended, Sponsor: National Cancer Institute (NCI)
Initiation date: May 2021 --> Aug 2021 Recruiting --> Suspended
- || Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
New P1 trial, Combination therapy: NCI-2021-01791: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - May 4, 2021
P1, N=20, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- | Oncaspar liquid (pegaspargase) / Servier
Trial completion, Phase classification: AALL08P1: Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) (clinicaltrials.gov) - Apr 27, 2021
P1, N=104, Completed, Sponsor: Children's Oncology Group
Recruiting --> Suspended Active, not recruiting --> Completed | Phase classification: PN/A --> P1
- | Asparlas (calaspargase pegol-mknl) / Servier, Takeda, Leadiant Biosci, Oncaspar liquid (pegaspargase) / Servier
Trial completion, Phase classification: AALL07P4: Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 27, 2021
P3, N=166, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Phase classification: PN/A --> P1 Active, not recruiting --> Completed | Phase classification: PN/A --> P3
- | Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 22, 2021
P1/2, N=37, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed | Phase classification: PN/A --> P3 Trial completion date: Oct 2026 --> Oct 2028 | Trial primary completion date: Oct 2021 --> Oct 2023
- | nelarabine / Generic mfg.
Trial completion date, Trial primary completion date: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 22, 2021
P2, N=160, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2026 --> Oct 2028 | Trial primary completion date: Oct 2021 --> Oct 2023 Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
- | Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
New P1 trial, Combination therapy: Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 19, 2021
P1, N=24, Not yet recruiting, Sponsor: Yazeed Sawalha
- | Venclexta (venetoclax) / Roche, AbbVie, DS-1594 / Daiichi Sankyo
Enrollment open, Trial initiation date, Combination therapy: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 7, 2021
P1/2, N=122, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2020 --> Oct 2021 Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> Mar 2021
- | Onureg (azacitidine oral) / BMS
Enrollment open: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Apr 1, 2021
P2/3, N=422, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> Mar 2021 Not yet recruiting --> Recruiting
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda
Enrollment open, Phase classification, Trial completion date, Trial primary completion date, Checkpoint inhibition: NCI-2018-03437: Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (clinicaltrials.gov) - Mar 30, 2021
P1/2, N=800, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | Trial completion date: Jul 2022 --> Jan 2023 | Trial primary completion date: Jul 2022 --> Jan 2023